{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:29:34Z","timestamp":1791322174513,"version":"4.3.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005075","name":"University Medical Center Groningen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005075","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00259-019-04489-z","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T05:03:57Z","timestamp":1566968637000},"page":"2496-2513","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Somatostatin receptor imaging by SPECT and PET in patients with chronic inflammatory disorders: a systematic review"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4725-1718","authenticated-orcid":false,"given":"Luz Kelly","family":"Anzola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andor W. J. M.","family":"Glaudemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudi A. J. O.","family":"Dierckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Andres","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Signore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"key":"4489_CR1","first-page":"256","volume":"47","author":"M Chianelli","year":"2003","unstructured":"Chianelli M, Parisela M, D\u00c1lessandria C, et al. The developing role of peptide radiopharmaceuticals in the study of chronic inflammation: new techniques for novel therapeutic options. Q J Nucl Med. 2003;47:256\u201369.","journal-title":"Q J Nucl Med"},{"key":"4489_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/00006231-199705000-00009","volume":"18","author":"M Chianelli","year":"1997","unstructured":"Chianelli M, Mather SJ, Martin-Comin J, et al. Radiopharmaceuticals for the study of inflammatory processes. A review. Nucl Med Commun. 1997;18:437\u201355.","journal-title":"Nucl Med Commun"},{"key":"4489_CR3","first-page":"197","volume":"59","author":"LK Anzola","year":"2015","unstructured":"Anzola LK, Galli F. Dierck RA. SPECT radiopharmeceuticals for imaging chronic inflammatory diseases in the last decade. Q J Nucl Med Mol Imaging. 2015;59:197\u2013213.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"4489_CR4","doi-asserted-by":"publisher","unstructured":"Bhanat E, Koch C, Paramr R, Garla V, Vijayakumar V. Somatostatine receptor expression in non-classical locations-clinical relevance? Reviews in Endocrine and Metabolic Disorders. \n                    https:\/\/doi.org\/10.1007\/s11154-018-9470-3\n                    \n                  .","DOI":"10.1007\/s11154-018-9470-3"},{"key":"4489_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2174\/1874471011306010006","volume":"6","author":"GL Cascini","year":"2013","unstructured":"Cascini GL, Cuccurullo V, Tamburrini O, et al. Peptide imaging with somatostatin analogues: more than cancer probes. Curr Radiopharm. 2013;6:36\u201340.","journal-title":"Curr Radiopharm"},{"key":"4489_CR6","first-page":"223","volume":"43","author":"J Sosabowski","year":"2003","unstructured":"Sosabowski J, Melendez A, Mather S. Radiolabelling of peptides for diagnosis and therapy of non-oncological disease. Q J Nucl Med. 2003;43:223\u201337.","journal-title":"Q J Nucl Med"},{"issue":"3","key":"4489_CR7","first-page":"225","volume":"49","author":"PF Rambaldi","year":"2005","unstructured":"Rambaldi PF, Cuccurullo V, Briganti V. The present and future role of 111In pentetreotide in the PET era. Q J Nucl Med Mol Imaging. 2005;49(3):225\u201335.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"179","key":"4489_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.179.4068.77","volume":"5","author":"P Brazeau","year":"1973","unstructured":"Brazeau P, Vale WW, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;5(179):77\u20139.","journal-title":"Science"},{"key":"4489_CR9","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1210\/endo-102-2-523","volume":"102","author":"YC Patel","year":"1978","unstructured":"Patel YC, Reichlin S. Somatostatin in hypothalamus, extrahypothalamic brain, and peripheral tissues of the rat. Endocrinology. 1978;102:523\u201330.","journal-title":"Endocrinology"},{"key":"4489_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.6004\/jnccn.2015.0012","volume":"13","author":"S Narayanan","year":"2015","unstructured":"Narayanan S, Kunz PL. Role of somatostatine analogues in the treatment of neuroendocrine tumors. J Natl Compr Cancer Netw. 2015;13:109\u201317.","journal-title":"J Natl Compr Cancer Netw"},{"key":"4489_CR11","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.jbspin.2004.02.006","volume":"71","author":"M Duet","year":"2004","unstructured":"Duet M, Liote F. Somatostatine and somatostatine analog scintigraphy: any benefits for rheumatology patients? Joint Bone Spine. 2004;71:530\u20135.","journal-title":"Joint Bone Spine"},{"key":"4489_CR12","first-page":"24","volume":"54","author":"GL Cascini","year":"2010","unstructured":"Cascini GL, Cuccurullo V, Mansi L. The non tumor uptake of 111In octreotide creates new clinical indications in benign diseases, but also in oncology. Q J Nucl Med Mol Imaging. 2010;54:24\u201336.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"4489_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1053\/j.semnuclmed.2011.02.001","volume":"41","author":"AP Wouter","year":"2011","unstructured":"Wouter AP, de Blois E, Chan HS, et al. 68Ga-labeled DOTA-peptides and 68Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med. 2011;41:314\u201321.","journal-title":"Semin Nucl Med"},{"key":"4489_CR14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3390\/jcm8050681","volume":"8","author":"A Signore","year":"2019","unstructured":"Signore A, Lauri C, Auletta S, Anzola K, Galli F, Casali M, et al. Immuno-imaging to predict treatment response in infection, inflammation and oncology. J Clin Med. 2019;8:681. \n                    https:\/\/doi.org\/10.3390\/jcm8050681\n                    \n                  .","journal-title":"J Clin Med"},{"key":"4489_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264\u20139.","journal-title":"Ann Intern Med"},{"key":"4489_CR16","unstructured":"Higgins JPTAD, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews."},{"key":"4489_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whitting","year":"2011","unstructured":"Whitting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529\u201336.","journal-title":"Ann Intern Med"},{"issue":"14","key":"4489_CR18","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jacc.2017.01.060","volume":"69","author":"JM Tarkin","year":"2017","unstructured":"Tarkin JM, Joshi FR, Evans NR, et al. Detection of atherosclerotic inflammation by 68Ga-DOTATATE PET compared to 18FFDG PET imaging. J Am Coll Cardiol. 2017;69(14):774\u201391.","journal-title":"J Am Coll Cardiol"},{"key":"4489_CR19","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2967\/jnumed.115.161216","volume":"56","author":"C Malmberg","year":"2015","unstructured":"Malmberg C, Ripa RS, Johnbeck CB, et al. 64Cu-DOTATATE for noninvasive assessment of atherosclerosis in large arteries and its correlation with risk factors: head-to-head comparison with 68Ga-DOTATOC in 60 patients. J Nucl Med. 2015;56:1895\u2013900.","journal-title":"J Nucl Med"},{"key":"4489_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.7150\/thno.7447","volume":"4","author":"I Velikyan","year":"2013","unstructured":"Velikyan I. Prospective of 68Ga-radiopharmaceutical development. Theranostics. 2013;4:47\u201380.","journal-title":"Theranostics."},{"key":"4489_CR21","doi-asserted-by":"publisher","first-page":"774","DOI":"10.2967\/jnumed.116.181438","volume":"58","author":"SMY Wan","year":"2017","unstructured":"Wan SMY, Endozo R, Michopoulou S, et al. PET\/CT imaging of unstable carotid plaque with 68 Ga-labeled somatostatin receptor ligand. J Nucl Med. 2017;58:774\u201380.","journal-title":"J Nucl Med"},{"key":"4489_CR22","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1161\/ATVBAHA.114.305067","volume":"35","author":"SF Pedersen","year":"2015","unstructured":"Pedersen SF, Sandholt VB, Keller SH, et al. 64Cu-DOTA-TATE PET\/MRI for detection of activated macrophages in carotid atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2015;35:1696\u2013703.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4489_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/2191-219X-2-52","volume":"2","author":"X Li","year":"2012","unstructured":"Li X, Samnick S, Lapa C, et al. 68Ga-DOTA-TATE PET\/CT for the detection of inflammation of large arteries: correlation with 18F-FDG, calcium burden and risk factors. EJNMMI Res. 2012;2:52\u201362.","journal-title":"EJNMMI Res"},{"issue":"1","key":"4489_CR24","first-page":"65","volume":"5","author":"A Mojtahedi","year":"2015","unstructured":"Mojtahedi A, Alavi A, Thamake S, et al. Assessment of vulnerable atherosclerotic and fibrotic plaques in coronary arteries using 68Ga-DOTATATE PET\/CT. Am J Nucl Med Mol Imaging. 2015;5(1):65\u201371.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"4489_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2967\/jnumed.109.070672","volume":"51","author":"A Rominger","year":"2010","unstructured":"Rominger A, Saam T, Vogl E, et al. In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET\/CT: correlation with coronary calcium burden and risk factors. J Nucl Med. 2010;51:193\u20137.","journal-title":"J Nucl Med"},{"key":"4489_CR26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cell.2011.04.005","volume":"145","author":"KJ Moore","year":"2011","unstructured":"Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341\u201355.","journal-title":"Cell"},{"key":"4489_CR27","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1189\/jlb.0606417","volume":"81","author":"C Armani","year":"2007","unstructured":"Armani C, Catalani E, Balbarini A, et al. Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. J Leukoc Biol. 2007;81:845\u201355.","journal-title":"J Leukoc Biol"},{"key":"4489_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11307-015-0873-1","volume":"18","author":"P Rinne","year":"2016","unstructured":"Rinne P, Hellberg S, Kiugel M, et al. Comparison of somatostatin receptor 2-targeting PET tracers in the detection of mouse atherosclerotic plaques. Mol Imaging Biol. 2016;18:99\u2013108.","journal-title":"Mol Imaging Biol"},{"key":"4489_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/138161282401180322163953","volume":"24","author":"A Signore","year":"2018","unstructured":"Signore A, Anzola LK, Auletta S, et al. Current status of molecular imaging in inflammatory and autoimmune disorders. Curr Pharm Des. 2018;24:1\u201311.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"4489_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13550-016-0202-y","volume":"6","author":"LK Anzola","year":"2016","unstructured":"Anzola LK, Chianelli M, Galli F, et al. Somatostatin receptor scintigraphy in patients with rheumatoid arthritis and secondary Sj\u00f6gren\u2019s syndrome treated with infliximab: a pilot study. EJNMMI Res. 2016;6(1):49\u201360.","journal-title":"EJNMMI Res"},{"issue":"10","key":"4489_CR31","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/art.1780371017","volume":"37","author":"PM Vanhagen","year":"1994","unstructured":"Vanhagen PM, Markusse MH, Lamberts SWJ, et al. Somatostatin receptor imaging the presence of somatostatin receptors in rheumatoid arthritis. Arthritis Rheum. 1994;37(10):1521\u20137.","journal-title":"Arthritis Rheum"},{"key":"4489_CR32","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/0014-2999(94)90796-X","volume":"271","author":"JC Reubi","year":"1994","unstructured":"Reubi JC, Waser B, Markusse HM, et al. Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. Eur J Pharmacol. 1994;271:371\u20138.","journal-title":"Eur J Pharmacol"},{"key":"4489_CR33","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.2174\/138161208785777414","volume":"14","author":"G Malviya","year":"2008","unstructured":"Malviya G, Signore A, Lagana B, et al. Radiolabelled peptides and monoclonal antibodies for therapy decision making in inflammatory diseases. Curr Pharm Des. 2008;14:2401\u2013014.","journal-title":"Curr Pharm Des"},{"key":"4489_CR34","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.2967\/jnumed.110.079962","volume":"51","author":"V Ambrosini","year":"2010","unstructured":"Ambrosini V, Zompatori M, De Lucca F, et al. Ga-DOTANOC PET\/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results. J Nucl Med. 2010;51:1950\u20135.","journal-title":"J Nucl Med"},{"key":"4489_CR35","first-page":"1281","volume":"47","author":"R Lebtahi","year":"2006","unstructured":"Lebtahi R, Moreau S, Marchan-Adam S, et al. Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. J Nucl Med. 2006;47:1281\u20137.","journal-title":"J Nucl Med"},{"issue":"2","key":"4489_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2310\/7290.2011.00030","volume":"11","author":"T Win","year":"2012","unstructured":"Win T, Screaton NJ, Porter J, et al. Novel positron emission tomography\/computed tomography of diffuse parenchymal lung disease combining a labeled somatostatin receptor analogue and 2-deoxy-2 18F Fluoro-D-glucose. Mol Imaging. 2012;11(2):91\u20138.","journal-title":"Mol Imaging"},{"key":"4489_CR37","first-page":"133","volume":"82","author":"F Aguirre-Balsalobre","year":"2007","unstructured":"Aguirre-Balsalobre F, Mengual-Verdu E, Mu\u00f1oz-Acosta JM, et al. Octreotide scintigraphy in thyroid orbitopathy. Arch Soc Esp Oftalmol. 2007;82:133\u201340.","journal-title":"Arch Soc Esp Oftalmol"},{"key":"4489_CR38","first-page":"3790","volume":"83","author":"A Colao","year":"1998","unstructured":"Colao A, Lastoria S, Ferone D, et al. Clinical response to corticosteroid therapy in patients with graves ophthalmopathy. J Clin Endocrinol Metab. 1998;83:3790\u20134.","journal-title":"J Clin Endocrinol Metab"},{"key":"4489_CR39","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1046\/j.1365-2265.1999.00681.x","volume":"50","author":"MN Gerdin","year":"1999","unstructured":"Gerdin MN, Van der Zan FM, Van Royen EA, et al. Octreotide-scintigraphy is a disease-activity parameter in graves ophthalmopathy. Clin Endocrinol. 1999;50:373\u20139.","journal-title":"Clin Endocrinol"},{"key":"4489_CR40","first-page":"553","volume":"39","author":"G Kahaly","year":"1998","unstructured":"Kahaly G, Rainer G, Diaz M, et al. Indium-111-pentetreotide in Graves\u2019 disease. J Nucl Med. 1998;39:553\u201336.","journal-title":"J Nucl Med"},{"key":"4489_CR41","first-page":"550","volume":"36","author":"G Kahaly","year":"1995","unstructured":"Kahaly G, Diaz M, Hahn K, et al. Indium-111-Pentetreotide scintigraphy in Graves\u2019 ophthalmopathy. J Nucl Med. 1995;36:550\u20134.","journal-title":"J Nucl Med"},{"key":"4489_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/thy.1999.9.47","volume":"9","author":"GE Krassas","year":"1999","unstructured":"Krassas GE, Doumas A, Kaltsas TH, et al. Somatostatin receptor scintigraphy before and after treatment with somatostatine analogues in patients with thyroid eye disease. Thyroid. 1999;9:47\u201352.","journal-title":"Thyroid."},{"key":"4489_CR43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1365-2265.1995.tb02682.x","volume":"42","author":"GE Krassas","year":"1995","unstructured":"Krassas GE, Doumas A, Pontikides N, et al. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol. 1995;42:571\u201380.","journal-title":"Clin Endocrinol"},{"key":"4489_CR44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/thy.1997.7.21","volume":"7","author":"R Moncayo","year":"1997","unstructured":"Moncayo R, Balsissera I, Decristoforo C, et al. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatine analogue 111In-octreotide. Thyroid. 1997;7:21\u20139.","journal-title":"Thyroid"},{"key":"4489_CR45","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s002590050419","volume":"26","author":"M Nocaudie","year":"1999","unstructured":"Nocaudie M, Bailliez A, Itti E, et al. Somatostatine receptor scintigraphy to predict the clinical evolution and therapeutic response of thyroid-associated ophthalmopathy. Eur J Nucl Med. 1999;26:511\u20137.","journal-title":"Eur J Nucl Med"},{"key":"4489_CR46","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1210\/jcem.79.6.7989493","volume":"79","author":"P Postema","year":"1994","unstructured":"Postema P, Krenning EP, Reubi JC, et al. 111In-DTPA-d-Phe1octreotide scintigraphy in thyroidal and orbital Graves\u2019s disease: a parameter for disease activity? J Clin Endocrinol Metab. 1994;79:1845\u201351.","journal-title":"J Clin Endocrinol Metab"},{"key":"4489_CR47","first-page":"1547","volume":"44","author":"G Burggasser","year":"2003","unstructured":"Burggasser G, Hurtl I, Hauff W, et al. Receptor tracer 99mTc-P829 in patients with Graves\u2019 disease. J Nucl Med. 2003;44:1547\u201355.","journal-title":"J Nucl Med"},{"key":"4489_CR48","first-page":"305","volume":"31","author":"H Sun","year":"2007","unstructured":"Sun H, Xu-Feng J, Wang S, et al. 99mTcHYNIC-TOC scintigraphy in evaluation of active Grave\u2019s ophthalmopathy (GO). Endocrinol. 2007;31:305\u201310.","journal-title":"Endocrinol"},{"issue":"2","key":"4489_CR49","first-page":"242","volume":"2","author":"R Zhao","year":"2012","unstructured":"Zhao R, Wang J, Deng J, Yang W, Wang J. Efficacy of 99mTcEDDA\/HYNIC-TOC SPECT\/CT scintigraphy in Graves\u2019 ophthalmopathy. Am J Nucl Med Mol Imaging. 2012;2(2):242\u20137.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"4489_CR50","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1089\/thy.2008.0389","volume":"19","author":"T Lincke","year":"2009","unstructured":"Lincke T, Singer J, Kluge R, et al. Relative quantification of indium-111 pentetreotide and gallium-68 DOTATOC uptake in the thyroid gland and association with thyroid pathologies. Thyroid. 2009;19:381\u20139.","journal-title":"Thyroid"},{"issue":"47","key":"4489_CR51","doi-asserted-by":"publisher","first-page":"77807","DOI":"10.18632\/oncotarget.12799","volume":"7","author":"C Lapa","year":"2016","unstructured":"Lapa C, Reiter T, Kircher M, et al. Somatostatine receptor based PET\/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI. Oncotarget. 2016;7(47):77807\u201314.","journal-title":"Oncotarget"},{"key":"4489_CR52","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s002590050297","volume":"25","author":"DJ Kwekkeboom","year":"1998","unstructured":"Kwekkeboom DJ, Krenning EP, Siang Kho G, et al. Somatostatine receptor imaging in patients with sarcoidosis. Eur J Nucl Med. 1998;25:1284\u201392.","journal-title":"Eur J Nucl Med"},{"key":"4489_CR53","first-page":"21","volume":"42","author":"R Lebtahi","year":"2001","unstructured":"Lebtahi R, Crestani B, Belmatoug N, et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med. 2001;42:21\u20136.","journal-title":"J Nucl Med"},{"key":"4489_CR54","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1097\/RLU.0000000000000977","volume":"40","author":"LS Kampuis","year":"2015","unstructured":"Kampuis LS, Kwekkeboom DJ, Missotten TO, et al. Somatostatine receptor scintigraphy patterns in patients with sarcoidosis. Clin Nucl Med. 2015;40:925\u20139.","journal-title":"Clin Nucl Med"},{"key":"4489_CR55","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13550-016-0207-6","volume":"6","author":"LC Gormsen","year":"2016","unstructured":"Gormsen LC, Haraldsen A, Kramer S, et al. A dual tracer 68-Ga-DOTANOC PET\/CT and 18F-FDG PET\/CT pilot study for detection of cardiac sarcoidosis. EJNMI Res. 2016;6:52\u201364.","journal-title":"EJNMI Res"},{"key":"4489_CR56","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s12149-016-1095-6","volume":"30","author":"T Nobashi","year":"2016","unstructured":"Nobashi T, Nakamoto Y, Kubo T, et al. The utility of PET\/CT with 68Ga-DOTATOC in sarcoidosis: comparison with Ga-scintigraphy. Ann Nucl Med. 2016;30:544\u201352.","journal-title":"Ann Nucl Med"},{"issue":"3","key":"4489_CR57","first-page":"98","volume":"122","author":"WJ Piotrowski","year":"2012","unstructured":"Piotrowski WJ, Bienkiwicz M, Frieske I, et al. Somatostatine receptor scintigraphy in sarcoidosis: relation to selected clinical and laboratory markers. Polskie Archiwum Medycyny Wewnetrznej. 2012;122(3):98\u2013105.","journal-title":"Polskie Archiwum Medycyny Wewnetrznej"},{"key":"4489_CR58","first-page":"1808","volume":"41","author":"P Weinmann","year":"2000","unstructured":"Weinmann P, Crestani B, Tazi A, et al. 111In-pentreotide scintigraphy in patients with Langerhans\u2019 cell histiocytosis. J Nucl Med. 2000;41:1808\u201312.","journal-title":"J Nucl Med"},{"issue":"2","key":"4489_CR59","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/00003072-199402000-00010","volume":"19","author":"E Ozt\u00fcrk","year":"1994","unstructured":"Ozt\u00fcrk E, G\u00fcnalp B, Ozg\u00fcven M, et al. The visualization of granulomatous disease with somatostatin receptor scintigraphy. Clin Nucl Med. 1994 Feb;19(2):129\u201332.","journal-title":"Clin Nucl Med"},{"issue":"6","key":"4489_CR60","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/BF00173035","volume":"21","author":"PM Vanhagen","year":"1994","unstructured":"Vanhagen PM, Krenning EP, Reubi JC, Kwekkeboom DJ, Bakker WH, Mulder AH, et al. Somatostatine analogue scintigraphy in granulomatous disease. Eur J Nucl Med. 1994;21(6):497\u2013502.","journal-title":"Eur J Nucl Med"},{"issue":"12","key":"4489_CR61","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s002590000347","volume":"27","author":"CM Aparici","year":"2000","unstructured":"Aparici CM, Narula J, Puig M, et al. Somatostatin receptor scintigraphy predicts impending cardiac allograft rejection before endomyocardial biopsy. Eur J Nucl Med. 2000 Dec;27(12):1754\u20139.","journal-title":"Eur J Nucl Med"},{"key":"4489_CR62","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/rheumatology\/keg479","volume":"43","author":"I Neumann","year":"2004","unstructured":"Neumann I, Mirszaei S, Birck R, et al. Expression of somatostatin receptors in inflammatory lesions and diagnostic value of somatostatin receptor scintigraphy in patients with ANCA-associated small vessel vasculitis. Rheumatology. 2004;43:195\u2013201.","journal-title":"Rheumatology"},{"key":"4489_CR63","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1007\/s00259-006-0317-x","volume":"34","author":"P Antunes","year":"2007","unstructured":"Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982\u201393.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4489_CR64","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s00259-007-0587-y","volume":"35","author":"C Pettinato","year":"2008","unstructured":"Pettinato C, Sarnelli A, Di Donna M, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008;35:72\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4489_CR65","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/thx.2007.078006","volume":"63","author":"R Borie","year":"2008","unstructured":"Borie R, Fabre A, Prost F, et al. Activation of somatostatin receptors attenuates pulmonary fibrosis. Thorax. 2008;63:251\u20138.","journal-title":"Thorax."},{"key":"4489_CR66","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s002590050213","volume":"25","author":"WAP Breeman","year":"1998","unstructured":"Breeman WAP, Martin Van Hagen P, Kwekkeboom DJ, Visser TJ, Krenning EP. Somatostatin receptor scintigraphy using 111In-DTPA-octreotide. Eur J Nucl Med. 1998;25:182\u20136.","journal-title":"Eur J Nucl Med"},{"key":"4489_CR67","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4321\/S0365-66912003000800004","volume":"78","author":"J P\u00e9rez Moreiras","year":"2003","unstructured":"P\u00e9rez Moreiras J, Coloma Bockos JE, Prada S\u00e1nchez MC. Orbitopat\u00eda tiroidea (fisiopatolog\u00eda, diagn\u00f3stico y tratamiento). Arch Soc Esp Oftalmol. 2003;78:407\u201331.","journal-title":"Arch Soc Esp Oftalmol"},{"key":"4489_CR68","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1210\/edrv-5-2-200","volume":"5","author":"DH Jacobson","year":"1984","unstructured":"Jacobson DH, Gorman CA. Endocrine ophthalmopathy: current ideas concerning etiology, pathogenesis and treatment. Endocr Rev. 1984;5:200\u201320.","journal-title":"Endocr Rev"},{"key":"4489_CR69","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1530\/eje.0.143s035","volume":"143","author":"A Colao","year":"2000","unstructured":"Colao A, Pivinello R, Lastoria S, et al. Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves\u2019 disease. Eur J Endocrinol. 2000;143:S35\u201342.","journal-title":"Eur J Endocrinol"},{"key":"4489_CR70","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/BF00834521","volume":"23","author":"PTE Postema","year":"1996","unstructured":"Postema PTE, Kwekkeboom DJ, Van Hagen PM, et al. Somatostatin-receptor scintigraphy in Graves\u2019s orbitopathy. Eur J Nucl Med. 1996;23:615\u20137.","journal-title":"Eur J Nucl Med"},{"key":"4489_CR71","doi-asserted-by":"publisher","first-page":"E344","DOI":"10.1152\/ajpendo.00048.2003","volume":"285","author":"VA Dalm","year":"2003","unstructured":"Dalm VA, van Hagen PM, van Koetsveld PM, et al. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am J Physiol Endocrinol Metab. 2003;285:E344\u201353.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"4489_CR72","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ejso.2009.01.007","volume":"35","author":"MU Khan","year":"2009","unstructured":"Khan MU, Khan S, El-Refaie S, et al. Clinical indications for Gallium-68 positron emission tomography imaging. Eur J Surg Oncol. 2009;35:561\u20137.","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"4489_CR73","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/BF00173035","volume":"21","author":"PM Vanhagen","year":"1994","unstructured":"Vanhagen PM, Krenning EP, Reubi JC, et al. Somatostatin analogue scintigraphy in granulomatous disease. Eur J Nucl Med. 1994 Jun;21(6):497\u2013502.","journal-title":"Eur J Nucl Med"},{"key":"4489_CR74","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1046\/j.1523-1755.1998.00807.x","volume":"53","author":"EC Hagen","year":"1998","unstructured":"Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int. 1998;53:743\u201353.","journal-title":"Kidney Int"},{"key":"4489_CR75","doi-asserted-by":"publisher","first-page":"925","DOI":"10.7326\/0003-4819-123-12-199512150-00005","volume":"123","author":"JK Rao","year":"1995","unstructured":"Rao JK, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feussner JR. The role of anti neutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Ann Intern Med. 1995;123:925\u201332.","journal-title":"Ann Intern Med"},{"key":"4489_CR76","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/(SICI)1096-9896(200002)190:3<349::AID-PATH524>3.0.CO;2-A","volume":"190","author":"L Harper","year":"2000","unstructured":"Harper L, Savage CO. Pathogenesis of ANCA-associated systemic vasculitis. J Pathol. 2000;190:349\u201359.","journal-title":"J Pathol"},{"key":"4489_CR77","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/0002-9343(83)91030-6","volume":"74","author":"GN Gephardt","year":"1983","unstructured":"Gephardt GN, Ahmad M, Tubbs RR. Pulmonary vasculitis (Wegener\u2019s granulomatosis) immunohistochemical study of T and B cell markers. Am J Med. 1983;74:700\u20134.","journal-title":"Am J Med"},{"key":"4489_CR78","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1006\/jaut.1993.1020","volume":"6","author":"N Rasmussen","year":"1993","unstructured":"Rasmussen N, Petersen J. Cellular immune responses and pathogenesis in c-ANCA positive vasculitides. J Autoimmun. 1993;6:227\u201336.","journal-title":"J Autoimmun"},{"key":"4489_CR79","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1093\/ndt\/14.7.1627","volume":"14","author":"F Ferrario","year":"1999","unstructured":"Ferrario F, Rastaldi MP. Necrotizing-crescentic glomerulonephritis in ANCA-associated vasculitis: the role of monocytes. Nephrol Dial Transpl. 1999;14:1627\u201331.","journal-title":"Nephrol Dial Transpl"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04489-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04489-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04489-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T23:14:59Z","timestamp":1598483699000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04489-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,28]]},"references-count":79,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["4489"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04489-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,28]]},"assertion":[{"value":"6 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare they have not conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}